Intuitive Surgical
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ISRG and other ETFs, options, and stocks.About ISRG
Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems.
ISRG Key Statistics
ISRG News
Intuitive Surgical (NYSE:ISRG) kicked off FY2024 on a high note. The market leader in minimally invasive, robotic-assisted surgery sustained double-digit revenu...
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded he...
Loading... Loading... Intuitive Surgical's ISRG short percent of float has fallen 3.96% since its last report. The company recently reported that it has 3.41 m...
Analyst ratings
61%
of 31 ratingsMore ISRG News
Dive Brief: The reaction of general surgeons to Intuitive Surgical’s da Vinci 5 has reinforced Truist Securities analysts' belief the new surgical robot will w...
Intuitive Surgical, Inc. (ISRG) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could sha...
Intuitive Surgical Inc (NASDAQ:ISRG) showcases robust revenue growth with a 11.5% increase in total revenue year-over-year. Net income attributable to Intuitiv...
Intuitive Surgical (ISRG) stock reversed lower midmorning Friday — erasing earlier gains — after analysts cautioned its da Vinci 5 launch will be initially slow...
The healthcare industry can be a good place to invest for the long term. Demand for healthcare is only going to rise as the number of seniors goes up, and gener...
Loading... Loading... Intuitive Surgical Inc ISRG reported better-than-expected results for its first quarter on Thursday. Intuitive Surgical reported first-q...
Intuitive Surgical ISRG reported first-quarter 2024 adjusted earnings per share (EPS) of $1.50, which beat the Zacks Consensus Estimate of $1.40 by 7.1%. The bo...